Articles from TriLink BioTechnologies

TriLink BioTechnologies and Alphazyme, both part of Maravai LifeSciences, have collaborated to launch CleanScribe™ RNA Polymerase, a novel enzyme that reduces double-stranded RNA (dsRNA) in mRNA production. The new product reduces dsRNA by up to 85%, helping to develop safer, more potent mRNA therapeutics.

Cygnus Technologies (Cygnus), TriLink BioTechnologies (TriLink®), both part of Maravai LifeSciences (NASDAQMRVI) have collaborated to launch Cygnus’ AccuRes™ Host Cell DNA Quantification Kits. Together, the companies have leveraged state-of-the-art technologies and reagents to develop an assay with unparalleled sensitivity and specificity to help produce safer, more stable biotherapeutics that surpass regulatory standards.

TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQMRVI) and global provider of life science reagents and services, is collaborating with the Johns Hopkins University to accelerate transformational research in RNA therapeutics and discovery. A new center within the Johns Hopkins Whiting School of Engineering will accelerate research and therapeutic development, leveraging TriLink’s leading RNA synthesis technology.

TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQMRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries. This agreement with Lonza strengthens TriLink’s objective to drive greater access to CleanCap® mRNA capping technologies as the demand for mRNA – a promising therapeutic modality – continues to grow.

TriLink BioTechnologies (TriLink®), a Maravai LifeSciences company (NASDAQMRVI) and global provider of life science reagents and services, has announced the grand opening of its new cGMP mRNA manufacturing facility. The 32,000-square-foot facility was specifically designed for mRNA manufacturing to support late-phase drug developers from Phase 2 to commercialization via TriLink’s robust mRNA manufacturing capabilities. The milestone opening is expected to help advance the field of mRNA-based medicine as developers flock to leverage the promising modality for a growing list of indications.

TriLink BioTechnologies (TriLink®), a Maravai LifeSciences company (NASDAQMRVI) and global provider of life science reagents and services, has been granted patents by the China National Intellectual Property Administration (CNIPA) and the Canadian Intellectual Property Office (CIPO). Patent numbers ZL 2023 1 0734863.0 and CA 2999274 are related to TriLink’s CleanCap® technology for the co-transcriptional capping of mRNAs – a critical component of the production of synthetic mRNA as drug developers and researchers strive to maximize the impact of mRNA-based therapeutics and vaccines.

TriLink BioTechnologies® (TriLink), a Maravai LifeSciences company (NASDAQMRVI) and global provider of life science reagents and services, has launched its Analytical Sciences Center of Excellence (ASCE) hub. Expanding its comprehensive suite of analytical testing capabilities, this new center of excellence will minimize the delays and unexpected costs typically associated with outsourced testing to multiple laboratories. This new center of excellence will serve as the hub for all analytical innovation and the Quality Control laboratories across the organization’s manufacturing network.

TriLink BioTechnologies (TriLink®), a Maravai LifeSciences company (NASDAQMRVI) and global provider of life science reagents and services, has announced the expansion of its mRNA manufacturing capabilities to serve late-phase drug developers. TriLink’s construction of the new 32,000-square-foot, cGMP-grade facility solidifies its commitment to advancing the field as more mRNA-based therapeutics and vaccines enter later-stage clinical trials.